Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
Abatacept was well tolerated by patients with early diffuse cutaneous systemic sclerosis. The primary endpoint was modified Rodnan Skin Score at 12 mo...
Recent Posts
-
-
What Causes Sciatica | Dr. Kalyan Bommakanti
11 May 2022 -
